Why Sionna Therapeutics, Inc.’s (SION) Stock Is Up 5.80%
As of Wednesday, September 02, Sionna Therapeutics, Inc.’s SION share price has surged by 5.80%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Sionna Therapeutics, Inc.’s (SION) Stock Is Up 7.46%
As of Tuesday, August 25, Sionna Therapeutics, Inc.’s SION share price has surged by 7.46%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Sionna Therapeutics, Inc.’s (SION) Stock Is Up 13.22%
As of Friday, August 21, Sionna Therapeutics, Inc.’s SION share price has surged by 13.22%, which has investors questioning if this is right time to sell.Michael Rose
Why Sionna Therapeutics, Inc.’s (SION) Stock Is Up 7.84%
As of Wednesday, August 12, Sionna Therapeutics, Inc.’s SION share price has surged by 7.84%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Sionna Therapeutics, Inc.’s (SION) Stock Is Up 20.00%
As of Wednesday, August 12, Sionna Therapeutics, Inc.’s SION share price has surged by 20.00%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SION | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $330.5 | $288.9 | 32% |
|
| Shares Out (Mil) | 45.1 | 54.0 | 45% |
|
| Institutional Ownership | 97.3% | 93.1% | 73% |
|
| Float (Mil) | 17.0 | 41.4 | 27% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,428 | 480 | 78% |
|
| Price Change (52-week) |
(71.2%) | 59.9% | 9% |
|
| Growth | SION | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.674) | ($2.564) | ($2.529) | |
| Month Ago EPS | ($0.651) | ($2.544) | ($2.802) | |
| # Rev Up | 1 | 2 | 1 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | ($0.651) | ($2.544) | ($2.802) | |
| Year/Year Chg | 1.8% | 36.2% | 58.3% | |
| Financials | SION | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($97) | ($43) | 11% |
|
| EPS (TTM) | ($2.168) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($76) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $22 | $2 | 63% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | ($21) | $190 | 1% |
|
| Valuation | SION | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.24 | 2.84 | 30% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SION | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (30.7%) | (47.7%) | 17% |
|
| ROE | (32.3%) | (55.0%) | 19% |
|
| Liabilities to Assets | 6.2% | 29.6% | 3% |
|
| F-Score | 1 | 3 | 1% |
|
Sionna Therapeutics, Inc. did not pass any screens on 9/2/2026.
